Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.

2.

A study outlines the need for policies that enhance cancer patients' autonomy and information.

3.

A study suggests that screening for liver cancer is beneficial for patients with cirrhosis.

4.

Prostate cancer screening program beneficial in top decile of polygenic risk score

5.

Atezolizumab + Cabozantinib Postpones mCRPC Progression.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot